Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NRX PharmaceuticalsNRXP -8.71%29 Gross Margin % is 40.92% as of Mar. 2026, which is 30% below its 10-year median of 58.78. GuruFocus rates NRXP with a GF Score™ of 29/100. The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, NRX Pharmaceuticals ranks worse than 59.35% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
NRX Pharmaceuticals had a gross margin of 40.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
NRX Pharmaceuticals Gross Margin % Related Terms
NRX Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for NRX Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRXP vs CRBP, PRQR, TNYA: Gross Margin % Comparison
For the Biotechnology subindustry, NRX Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NRX Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
NRX Pharmaceuticals (NRXP) has a Gross Margin % of 40.92% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on NRX Pharmaceuticals and its competitors. This is 30% below median its historical median of 58.78. Over the past decade, NRX Pharmaceuticals' Gross Margin % has ranged from 50.46 to 58.78. According to the industry distribution chart, NRX Pharmaceuticals ranks #435 out of 733 companies in the Biotechnology industry, placing it in the top 59.3%.
Is NRX Pharmaceuticals' Gross Margin % too high?
NRX Pharmaceuticals' current Gross Margin % of 40.92% is 30% below median its 10-year median of 58.78. Over the past 10 years, this metric has ranged from a low of 50.46 to a high of 58.78. The Biotechnology industry median Gross Margin % is 60.90. NRX Pharmaceuticals' value of 40.92% is 32.8% below this industry median. Based on the distribution chart, NRX Pharmaceuticals ranks #435 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, NRX Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NRX Pharmaceuticals' Gross Margin % compare to CRBP and PRQR?
According to the Biotechnology industry distribution chart, NRX Pharmaceuticals ranks #435 out of 733 companies for Gross Margin %. This places NRX Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 60.90. NRX Pharmaceuticals' value of 40.92% is 32.8% below this benchmark. Historically, NRX Pharmaceuticals' own Gross Margin % has ranged from 50.46 to 58.78 over the past decade. While the company's 10-year median is 58.78 vs. the industry median of 60.90, NRX Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NRX Pharmaceuticals's current Gross Margin % of 40.92% is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on NRX Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NRX Pharmaceuticals's current Gross Margin % is 40.92%, which is 30% below median its own 10-year median of 58.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NRX Pharmaceuticals stock overvalued right now?
NRX Pharmaceuticals (NRXP) has a current Gross Margin % of 40.92%. The current Gross Margin % is 40.92%, which is 30% below median its 10-year median of 58.78 and 32.8% below the Biotechnology industry median of 60.90. NRX Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For NRX Pharmaceuticals (NRXP), the current Gross Margin % is 40.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
29GF Score
Get the complete analysis for NRXP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRXP has been successfully added to your 
